Electrocore Stock Price, News & Analysis

electroCore reported strong first quarter 2022 results with $1.9 million in product sales, up 60% year-over-year and 27% sequentially. The revenue from government channels reached $1.26 million, demonstrating 47% growth from Q4 2021, while commercial channels generated $300,000, up 11% from Q4 2021. However, international sales fell by 20% compared to Q1 2021 due to COVID impacts. The company ended the quarter with a cash balance of $29.9 million, down from $34.7 million at year-end 2021.

electroCore has entered an exclusive licensing agreement with Teijin Limited to commercialize its non-invasive vagus nerve stimulation (nVNS) technology in Japan for treating primary headache disorders. The deal includes a non-refundable upfront payment, milestone payments upon product commercialization, and an annual license fee starting after the first anniversary. Teijin will cover regulatory costs and can negotiate additional licenses for other indications. This collaboration aims to improve healthcare for headache sufferers and supports electroCore's global expansion efforts.

electroCore, Inc. (NASDAQ: ECOR) announced that its co-founder and Chief Medical Officer, Dr. Peter Staats, will keynote the Fifth Annual Bioelectronic Medicine Forum on April 5, 2022, in New York City. This event will focus on bioelectronic medicine technologies and their applications across various medical fields, including cardiovascular and gastrointestinal disorders. Dr. Staats holds significant leadership roles in multiple medical societies and is dedicated to advancing non-invasive vagus nerve stimulation therapy aimed at improving patient outcomes in treating migraine and cluster headaches.

electroCore announced that CEO Dan Goldberger will present at the 2022 Maxim Virtual Growth Conference from March 28-30, 2022. The presentation will be available on-demand, providing insights into the company's advancements in bioelectronic medicine. electroCore focuses on non-invasive vagus nerve stimulation therapy for the treatment of conditions like migraines and cluster headaches. The company's solutions aim to improve patient outcomes in neurology. Stakeholders can access the presentation and more information via the provided link.

electroCore reported a significant 56% increase in full-year net sales for 2021, totaling approximately $5.5 million, compared to $3.5 million in 2020. The fourth quarter recorded net sales of $1.5 million, marking a 61% growth year-over-year. Cash balances stood at $34.7 million as of December 31, 2021. The company has launched new online purchasing platforms and achieved a 69% increase in sales to the VA and DoD. However, a GAAP net loss of $17.2 million was reported for the year, down from $23.5 million in 2020.

electroCore, Inc. (Nasdaq: ECOR) announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to its Board of Directors, effective March 15, 2022. This move aims to bolster the company's marketing and brand strategy as it focuses on direct-to-consumer initiatives. The appointments follow the resignation of Dr. Stephen Ondra, who is transitioning to a new role, and Michael Atieh, who will not seek re-election. Both Goldstein and Wilber bring extensive marketing expertise from leading organizations, including Disney and JIVE Records, which could enhance electroCore’s growth prospects.

electroCore, a bioelectronic medicine company (NASDAQ: ECOR), announced its participation in the 34th Annual Roth Conference on March 14, 2022, at 8:30 AM PDT. The presentation will be accessible to investors who can register online. Following the event, a webcast replay will be available on the company's investor website. The company focuses on improving patient outcomes through its non-invasive vagus nerve stimulation therapy, targeting conditions such as migraines and cluster headaches.

electroCore, Inc. (Nasdaq: ECOR) will report its financial results for Q4 and the year ending December 31, 2021, on March 10, 2022. A conference call will follow at 4:30 PM EST to discuss results and answer questions. The company's focus is on non-invasive vagus nerve stimulation therapy for treating conditions like migraines and cluster headaches.

electroCore (Nasdaq: ECOR) announced promising results from clinical trials presenting at the 2022 International Stroke Conference. The trials explored the use of non-invasive Vagus Nerve Stimulation (nVNS) for treating acute stroke. Key findings showed a 65.9% reduction in relative ischemic lesion growth for nVNS compared to sham treatment. The trials indicated that nVNS was administered safely and met both primary and secondary endpoints. The company anticipates further research to establish nVNS's efficacy in stroke treatment.